Last reviewed · How we verify

NCT06096805

Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)

Recruiting now Last updated 7 June 2024
What this trial tests

trial in Fetal Growth Retardation in 2,000 participants. Currently enrolling.

Timeline
10 August 2023
Primary endpoint
30 December 2025
30 December 2025

Quick facts

Lead sponsorShanghai First Maternity and Infant Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment2,000
Start date10 August 2023
Primary completion30 December 2025
Estimated completion30 December 2025
Sites1 location across China

Conditions studied

Sponsor

Shanghai First Maternity and Infant Hospital

Who can join

Adults 18 to 45, female only, with Fetal Growth Retardation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to prospectively enroll high-risk pregnant women to establish a multicenter cohort. By combining maternal basic characteristics, medical history, early pregnancy ultrasound, and biological markers, we aim to construct a joint predictive model for MVM-FGR.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Fetal Growth Retardation

Currently open trials in the same condition.

Other Shanghai First Maternity and Infant Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing